Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Discovery of the First Druggable GPR52 Antagonist to Treat Huntington's Disease.

Journal of medicinal chemistry - 28 Jan 2021

Komatsu Hidetoshi

Abstract excerpt

GPR52 is an orphan G protein-coupled receptor (GPCR) highly expressed in the brain, especially in the striatum, and represents an emerging therapeutic target for Huntington's disease (HD), an incurable monogenic neurodegenerative disorder caused by the mutation of the huntingtin (mHTT) gene. This Viewpoint discusses the discovery, published in this journal, that a highly potent and specific GPR52 antagonist was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Discovery
Share to High-Throughput Screening Assays
Share to Huntingtin Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Huntington Disease

Share to Receptors, G-Protein-Coupled

Share to RNA, Small Interfering

Share to Structure-Activity Relationship

Source

Identifiers

PMID: 33443413
DOI: 10.1021/acs.jmedchem.0c02235

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Discovery of the First Druggable GPR52 Antagonist to Treat Huntington's Disease.PMID 33443413Read ↗

Targeting Gpr52 lowers mutant HTT levels and rescues Huntington's disease-associated phenotypes.Semantic proximity Read ↗

A striatal-enriched intronic GPCR modulates huntingtin levels and toxicity.Semantic proximity Read ↗

The Emerging Landscape of Small-Molecule Therapeutics for the Treatment of Huntington’s DiseaseSemantic proximity Read ↗

A Critical Evaluation of Adenosine A2A Receptors as Potentially &#x201C;Druggable&#x201D; Targets in Huntingtons DiseaseSemantic proximity Read ↗

Development of novel therapies for Huntington's disease: hope and challenge.Semantic proximity Read ↗

Adenosine receptors and Huntington's disease: implications for pathogenesis and therapeutics.Semantic proximity Read ↗

New therapeutic opportunities for 5-HT2 receptor ligandsSemantic proximity Read ↗

A Monoclonal Antibody TrkB Receptor Agonist as a Potential Therapeutic for Huntington’s DiseaseSemantic proximity Read ↗

Novel compounds that reverse the disease phenotype in Type 2 Gaucher disease patient-derived cells.Semantic proximity Read ↗

Positron Emission Tomography (PET) Imaging Tracers for Serotonin ReceptorsSemantic proximity Read ↗

Discovery of a Highly Selective and H435R-Sensitive Thyroid Hormone Receptor β Agonist.Semantic proximity Read ↗

Identification and Characterization of a Small Molecule Ligand for the Huntingtin-HAP40 ComplexSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.